Related Experiment Videos
Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.
Kelly A Newell1, Chao Deng, Xu-Feng Huang
1Neurobiology Research Center for Metabolic and Psychiatric Disorders, School of Health Sciences, University of Wollongong, Northfields Avenue, Wollongong, NSW, 2522, Australia. kan02@uow.edu.au
Experimental Brain Research
|May 20, 2006
Summary
Schizophrenia is linked to changes in the brain's cannabinoid system. This study found increased CB1 receptor binding in the posterior cingulate cortex (PCC) of schizophrenia patients, suggesting a role for the endogenous cannabinoid system.
Area of Science:
- Neuroscience
- Psychiatry
- Receptor Pharmacology
Background:
- The posterior cingulate cortex (PCC) is increasingly recognized for its role in schizophrenia pathophysiology.
- Previous research indicates alterations in glutamate, GABA, and muscarinic receptors in the PCC in schizophrenia.
- Evidence suggests the endogenous cannabinoid system may also be dysregulated in schizophrenia.
Purpose of the Study:
- To investigate the binding density of CB1 receptors in the PCC of individuals with schizophrenia compared to healthy controls.
- To explore the potential involvement of the endogenous cannabinoid system in the neurobiology of schizophrenia.
Main Methods:
- Quantitative autoradiography was employed to measure [(3)H]CP-55940 binding to CB1 receptors.
- The study compared CB1 receptor binding in the PCC between schizophrenia subjects and control participants.
- Exclusion criteria included recent cannabis use in control subjects.
Main Results:
- A significant 25% increase in CB1 receptor binding was observed in the superficial layers (I, II) of the PCC in schizophrenia subjects.
- No significant differences in CB1 binding were found in the deeper layers (III-VI) of the PCC between groups.
- CB1 binding density did not correlate with demographic or postmortem variables, including antipsychotic dose.
Conclusions:
- The findings demonstrate an elevated density of CB1 receptors in the PCC of individuals with schizophrenia.
- This increase supports the hypothesis that the endogenous cannabinoid system plays a role in the pathophysiology of schizophrenia.
- Further research into the modulation of CB1 receptors may offer novel therapeutic targets for schizophrenia.